Here, we examined the association between immune checkpoint‐related gene (PD1, LAG3, TIM3, and TIGIT) polymorphisms and susceptibility, clinical variables, risk stratification, response to chemotherapy, relapse, and survival of AML. This evidence concerns the gene LAG3 and acute myeloid leukemia.